Axogen Inc Stock Price, News & Analysis

Axogen (NASDAQ: AXGN) reported expected fourth quarter revenue of approximately $31.5 million, down 3% from $32.5 million in Q4 2020. For the full year 2021, revenue is projected to be around $127.3 million, marking a 13% increase from $112.3 million in 2020. The decline in Q4 revenue is attributed to surgical volume fluctuations and COVID-19 impacts. The company expanded its sales force and core accounts, with 294 Core Accounts, a 9% increase year-over-year. Axogen anticipates releasing RECON study results in Q2 2022.

Axogen (AXGN) will feature its nerve repair platform at the combined 2022 meetings of the American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery from January 11-18 in Carlsbad, CA. An educational symposium on January 13 will discuss evidence-based nerve repair strategies. Key presentations include studies on nerve grafts and reconstruction techniques. CEO Karen Zaderej emphasized the growing interest in peripheral nerve repair and Axogen's commitment to patient outcomes through innovative solutions.

Axogen, Inc. (NASDAQ: AXGN) announces that patient Christopher Brown will feature in the 2022 Donate Life Rose Parade Float, honoring organ donor Paul Flanders. The event, aimed at raising awareness for organ and tissue donation, will take place on New Year’s Day in Pasadena, CA. Brown's recovery from chronic pain due to nerve damage after an amputation was made possible through nerve repair surgery using donated tissue. Axogen's CEO, Karen Zaderej, emphasized the importance of donation and the company's commitment to improving quality of life for nerve injury patients.

Axogen, Inc. (NASDAQ: AXGN) announced that CEO Karen Zaderej will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 10:00 a.m. ET. The presentation will be available via live webcast on Axogen's Investors page, with a recorded replay accessible for 90 days post-event. Axogen specializes in innovative surgical solutions for peripheral nerve injuries, offering products like Avance^® Nerve Graft and Axoguard^® devices that aid in nerve repair and regeneration.

Axogen, Inc. (NASDAQ: AXGN) announced that CEO Karen Zaderej will present at the Jefferies London Healthcare Conference on November 17, 2021, at 4:25 p.m. (11:25 a.m. ET). The presentation will be streamed live on the company's Investors page, with a replay available for 90 days. Axogen specializes in innovative surgical solutions for peripheral nerve injuries, aiming to restore nerve function and quality of life for patients. Their product portfolio includes Avance® Nerve Graft and Axoguard series, designed to effectively repair peripheral nerves.

Axogen, Inc. (NASDAQ: AXGN) reported Q3 2021 net revenue of $31.2 million, a 7% decline from $33.4 million in Q3 2020. The net loss increased to $7.1 million, or $0.17 per share, compared to a net loss of $1.5 million, or $0.04 per share, in the prior year. Despite lower procedure volumes due to COVID-19 challenges, gross margin improved to 83.2%. The company revised its 2021 revenue guidance to between $127 million and $129 million, down from the previous estimate of $134.5 million to $137.5 million.

Axogen (NASDAQ: AXGN) will report its third quarter 2021 financial results on November 3, 2021, after market close. Following this, management will host a conference call at 4:30 p.m. ET to discuss the results. Interested investors can participate via phone or listen to the webcast on the company's website. Axogen specializes in surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard Nerve Protector® to aid in nerve repair and regeneration, thus improving patients' quality of life.

Axogen, a leader in surgical solutions for peripheral nerve damage, will participate in the 76th Annual Meeting of the American Society for Surgery of the Hand (ASSH) from September 30-October 2, 2021 in San Francisco. The company will host a symposium on October 1, featuring an expert panel discussing the impact of Axogen technologies on nerve repair practices. Attendees can engage with Axogen scientists and explore innovative surgical techniques at Booth #950. Axogen will also support educational initiatives and offer travel scholarships for attendees.

Axogen announced the completion of subject follow-up for its pivotal RECON Clinical Study, supporting the Biologics License Application (BLA) for Avance® Nerve Graft. The study met its enrollment target of 220 subjects in July 2020 and is on track for a top-line data read-out in Q2 2022, followed by BLA submission in 2023. The RECON study aims to provide Level 1 clinical data, comparing Avance Nerve Graft to manufactured conduits in digital nerve injuries, focusing on recovery of sensation and quality of life outcomes.